Immuneering (IMRX) Common Equity (2020 - 2026)
Immuneering (IMRX) reported Common Equity of $190.74 million for Q2 2026, up 559.2% from $28.94 million a year earlier but down 7.6% from the prior quarter.
Powered by 
Analysis
Immuneering (IMRX) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Immuneering posted Common Equity of $218.48 million, up 427.9% from FY2024.
- By year, Common Equity came in at $41.39 million in FY2024 (-54.3%), $90.58 million in FY2023 (-17.5%), $109.85 million in FY2022 (-29.6%) and $155.98 million in FY2021.
- Five-year quarterly Common Equity spans a low of $28.94 million in Q2 2025 and a high of $227.98 million in Q3 2025.
- Year over year, Common Equity has now increased in each of the last four quarters, with growth averaging 184.2% over the last eight quarters.
- The high point for year-over-year Common Equity in five years was Q2 2026 (growth of 559.2%); the low point was Q2 2025 (a decline of 56.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $206.52 million (Q1 2026), $218.48 million (Q4 2025) and $227.98 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Immuneering | 269.14 Mn | 269.14 Mn | - | 190.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 190.74 Mn |
| Mar 31, 2026 | 206.52 Mn |
| Dec 31, 2025 | 218.48 Mn |
| Sep 30, 2025 | 227.98 Mn |
| Jun 30, 2025 | 28.94 Mn |
| Mar 31, 2025 | 41.84 Mn |
| Dec 31, 2024 | 41.39 Mn |
| Sep 30, 2024 | 57.72 Mn |
| Jun 30, 2024 | 66.31 Mn |
| Mar 31, 2024 | 78.72 Mn |
| Dec 31, 2023 | 90.58 Mn |
| Sep 30, 2023 | 104.02 Mn |
| Jun 30, 2023 | 115.10 Mn |
| Mar 31, 2023 | 97.79 Mn |
| Dec 31, 2022 | 109.85 Mn |
| Sep 30, 2022 | 121.89 Mn |
| Jun 30, 2022 | 133.59 Mn |
| Mar 31, 2022 | 144.06 Mn |
| Dec 31, 2021 | 155.98 Mn |
| Sep 30, 2021 | 158.29 Mn |
API Access
Immuneering Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=IMRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "IMRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=IMRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();